All Stocks/Healthcare/TNDM

TANDEM DIABETES CARE INC

TNDM
HealthcareMedical Devices Website
Price ChartPowered by TradingView
Ask about TNDMAI research agent
Top Institutional HoldersFrom 13F filings
FundShares HeldPosition ValueAction (latest Q)
Citadel
Ken Griffin
2.15M$47.30MNEW
D.E. Shaw
David Shaw
924K$20.32MNEW
Marshall Wace876K$19.24MNEW
Politicians who traded TNDMFrom Senate & House PTRs
PoliticianDateTypeAmount
Gilbert Cisneros
D-CA
2026-03-03purchase$1k – $15k
Josh Gottheimer
D-NJ
2025-09-22purchase$1k – $15k
Josh Gottheimer
D-NJ
2025-03-19sale$1k – $15k
Daniel Goldman
NY
2023-07-12sale$1k – $15k
Thomas MacArthur
NJ
2015-05-27sale$1k – $15k
About TANDEM DIABETES CARE INC

Tandem Diabetes Care designs, develops, and commercializes advanced technology solutions for insulin-dependent diabetes management worldwide. The company's flagship products are the t:slim X2 insulin pump and the Tandem Mobi automated insulin delivery system, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology that helps optimize blood glucose levels. These durable insulin pumps work alongside continuous glucose monitoring systems, including integration with Abbott's FreeStyle Libre 3 Plus sensor. Tandem also manufactures disposable products such as infusion sets and cartridges for insulin storage and delivery. Nearly three-quarters of revenue derives from the United States, with the remainder primarily from other developed nations. The company serves individual patients with insulin-dependent diabetes across multiple distribution channels, including direct sales, pharmacy partnerships, and healthcare providers. Founded in 2006 and headquartered in San Diego, California, Tandem operates as a global leader in automated insulin delivery technology.

CEO
Mr. John F. Sheridan
Employees
2,500
Quick Facts
Exchange–
SectorHealthcare
IndustryMedical Devices
Market Cap–
Key Dates

Earnings calendar coming soon. Subscribe to get notified when TNDM reports next.

Get earnings alerts →